Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases
Lippert AH. et al, (2024), Immunity
Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis
Kaufmann M. et al, (2021), Med, 2, 296 - 312.e8
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
Wurm H. et al, (2020), Multiple Sclerosis Journal, 26, 1261 - 1264
A novel neurodegenerative spectrum disorder in patients with MLKL deficiency.
Faergeman SL. et al, (2020), Cell Death Dis, 11
Structural and regulatory diversity shape HLA-C protein expression levels
Kaur G. et al, (2017), Nature Communications, 8
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
Dendrou CA. et al, (2016), Science Translational Medicine, 8
Multiple sclerosis
Rühl G. et al, (2016), Neurology - Neuroimmunology Neuroinflammation, 3, e241 - e241
Class II HLA interactions modulate genetic risk for multiple sclerosis
(2015), Nature Genetics, 47, 1107 - 1113
CD8+MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis
Willing A. et al, (2014), European Journal of Immunology, 44, 3119 - 3128
TCR Transgenic Mice That Shed Light on Immune and Environmental Regulators in Multiple Sclerosis
Attfield KE. and Fugger L., (2013), The Journal of Immunology, 190, 3015 - 3017
TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis
Gregory AP. et al, (2012), Nature, 488, 508 - 511
Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosis
Attfield KE. et al, (2012), Immunological Reviews, 248, 10 - 22
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model
Vergo S. et al, (2011), Brain, 134, 571 - 584
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model
Vergo S. et al, (2011), Brain, 134, 571 - 584
The role of antigenic modulation in controlling the efficacy of anti-CD20 monoclonal antibodies
Beers SA. et al, (2008), IMMUNOLOGY, 125, 48 - 49
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Beers SA. et al, (2008), Blood, 112, 4170 - 4177
Invariant NKT Cells Promote CD8+ Cytotoxic T Cell Responses by Inducing CD70 Expression on Dendritic Cells
Taraban VY. et al, (2008), The Journal of Immunology, 180, 4615 - 4620